Skip to main content

Table 1 Summary of efficacy evaluations according to patient subgroup

From: Degarelix therapy for prostate cancer in a real-world setting: experience from the German IQUO (Association for Uro-Oncological Quality Assurance) Firmagon® registry

 

Patient subgroup

Evaluation

All patients

Patients with metastatic disease

Prior HTa

No prior HT

Baseline PSA ≥20 ng/ml

Prior LHRH analogue therapyb

No prior LHRH analogue therapy

Tumour response

      

Overall survival

 

 

PSA progression-free survival

   

Percentage change in median PSA

   

Percentage change in median testosterone

   

Percentage change in median S-ALP

 

 

   

Mean prostate volume

      

Percentage of patients with PSA ≤ 4 ng/ml

  

  
  1. aLHRH agonists, GnRH antagonists or antiandrogens; bLHRH agonists or GnRH antagonists